Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Drug Discovery and Development
Sort By
Newest First
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
(1069)
1 / 54
LAIs
Seven Biotechs Developing Long-Acting Injectable Drugs
Vedangi Joshi
Nice Insight
PAO-08-26-PA-10
Aug 10, 2026
Cell Therapy
NueCell Bio Launches as a New Translational Partner to Accelerate Cell Therapies from Discovery into GMP Manufacturing
NueCell Bio
PR-08-26-01
Aug 5, 2026
In Vivo CAR-T
Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic
Emma Gormlie
Nice Insight
PAO-07-26-PA-13
Jul 30, 2026
Combination Products
Collaboration is Key to Successful Injectable Drug–Device Combination Product Development
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-05
Jul 27, 2026
Oncology
Harnessing Macrophage Biology to Overcome Tumor Immune Evasion
Roy Maute, Ph.D.
Pheast Therapeutics
PAO-07-26-CL-03
Jul 23, 2026
Stem Cells
Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-26-PA-11
Jul 22, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19
Jul 20, 2026
Rare Cancer CGT
Developing Cell and Gene Therapies for Rare Oncology Applications
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-10
Jul 16, 2026
Drug Delivery
Intracellular Delivery: Reaching Targets Beyond the Cell Surface
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-07
Jul 14, 2026
Tumor-Agnostic
Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-05
Jul 8, 2026
Next-Gen Delivery
Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms
Pharma's Almanac
PAO-07-26-PA-06
Jul 6, 2026
Protein Conformation
Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-17
Jul 6, 2026
Organoids
Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research
Seahee Kim, Ph.D.
Samsung Biologics
PAO-06-26-CL-04
Jul 1, 2026
LAIs
The Long View: How Extended-Duration Therapies Are Reshaping Patient Care
Pharma's Almanac
PAO-07-26-PA-01
Jul 1, 2026
Genome Engineering
Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-16
Jun 29, 2026
Microbiome Editing
Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-15
Jun 22, 2026
CNS Clinical
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969
Insilico Medicine
PR-06-26-01
Jun 17, 2026
Expedited Pathways
Accelerated Pathways: Are They Delivering on Their Promise?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-10
Jun 17, 2026
Protein Misfolding
Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-08
Jun 15, 2026
Alzheimer Therapies
Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-05
Jun 10, 2026
1 / 54